News & Perspective

"I would view the results . . . in an optimistic light," said lead author Richard Davey after the drug showed more than 90% efficacy.

Meanwhile, a different study met with disappointing results for an experimental Ebola drug in the Sierra Leone trial.

Findings include neurologic problems and a potential for virus survival in semen for 18 months.

The child's case is the 4th—including a death—from the same family in Forecariah district.

Also, phase 2 trials just launched for two prime-boost Ebola vaccine regimens.

Funding will be used to continue trials of BCX4430 and prepare for its large-scale manufacture.